keyword
MENU ▼
Read by QxMD icon Read
search

Aronne

keyword
https://www.readbyqxmd.com/read/28292399/current-and-future-medical-treatment-of-obesity
#1
REVIEW
Devika Umashanker, Leon I Igel, Rekha B Kumar, Louis J Aronne
Obesity is a major health crisis resulting in comorbidities such as hypertension, type 2 diabetes, and obstructive sleep apnea. The need for safe and efficacious drugs to help assist with weight loss and reduce cardiometabolic risk factors is great. With several FDA-approved drugs on the market, there is still a great need to develop long-term obesity treatments or noninvasive oral agents to help assist individuals with obesity when used in conjunction with lifestyle modifications.
April 2017: Gastrointestinal Endoscopy Clinics of North America
https://www.readbyqxmd.com/read/28271432/pharmacotherapy-for-weight-management-in-the-vha
#2
Todd P Semla, Chris Ruser, Chester B Good, Susan Z Yanovski, Donna Ames, Laurel A Copeland, Charles Billington, U Inge Ferguson, Louis J Aronne, Thomas A Wadden, W Timothy Garvey, Caroline M Apovian, David Atkins
Weight management medications (WMM) are underutilized as an adjunct to behavioral and lifestyle interventions. In fiscal years 2014-2015, a total of approximately 2500 veterans-a mere 2% of veterans receiving care from the Veterans Health Administration (VHA)-eligible for a WMM received a prescription for one. A State of the Art Conference on Weight Management workgroup, focused on pharmacotherapy, developed evidence-based recommendations and strategies to foster the appropriate use of WMM in the VHA. The workgroup identified patient, prescriber, and health system barriers to and facilitators for prescribing WMM...
March 7, 2017: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/28242319/white-paper-aga-power-practice-guide-on-obesity-and%C3%A2-weight-management-education-and-resources
#3
REVIEW
Andres Acosta, Sarah Streett, Mathew D Kroh, Lawrence J Cheskin, Katherine H Saunders, Marina Kurian, Marsha Schofield, Sarah E Barlow, Louis Aronne
The epidemic of obesity continues at alarming rates, with a high burden to our economy and society. The American Gastroenterological Association understands the importance of embracing obesity as a chronic, relapsing disease and supports a multidisciplinary approach to the management of obesity. Because gastrointestinal disorders resulting from obesity are more frequent and often present sooner than type 2 diabetes mellitus and cardiovascular disease, gastroenterologists have an opportunity to address obesity and provide an effective therapy early...
February 24, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28192104/practical-use-of-pharmacotherapy-for-obesity
#4
Leon I Igel, Rekha B Kumar, Katherine H Saunders, Louis J Aronne
Obesity management requires a multidisciplinary approach, as there are many factors that contribute to the development of obesity as well as the preservation of excess weight once it has been gained. Diet, exercise and behavior modification are key components of treatment. In addition to lifestyle changes, weight gain secondary to medications is an important modifiable risk factor. Even after appropriate lifestyle modification, and medication adjustments (where possible) to avoid agents that can contribute to weight gain, many patients are still unable to achieve clinically meaningful weight loss...
February 9, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28087864/drug-induced-weight-gain-rethinking-our-choices
#5
REVIEW
Katherine H Saunders, Leon I Igel, Alpana P Shukla, Louis J Aronne
Weight gain secondary to medications is a potentially modifiable risk. Here's how to optimize drug choices for patients with several common conditions.
November 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/28033472/obesity-coverage-on-medical-licensing-examinations-in-the-united-states-what-is-being-tested
#6
Robert F Kushner, W Scott Butsch, Scott Kahan, Sriram Machineni, Stephen Cook, Louis J Aronne
Phenomenon. As one of the most common chronic disease affecting adults and children, obesity is a major contributor to noncommunicable diseases, both nationally and globally. Obesity adversely affects every organ system, and as such it is imperative that the United States Medical Licensing Examination (USMLE) adequately assesses students' knowledge about the science and practice of obesity management. The purpose of this study was to evaluate the coverage and distribution of obesity-related items on the three USMLE Step examinations...
December 29, 2016: Teaching and Learning in Medicine
https://www.readbyqxmd.com/read/28017845/endoscopic-sleeve-gastroplasty-significantly-reduces-body-mass-index-and-metabolic-complications-in-obese-patients
#7
Reem Z Sharaiha, Nikhil A Kumta, Monica Saumoy, Amit P Desai, Alex M Sarkisian, Andrea Benevenuto, Amy Tyberg, Rekha Kumar, Leon Igel, Elizabeth C Verna, Robert Schwartz, Christina Frissora, Alpana Shukla, Louis J Aronne, Michel Kahaleh
BACKGROUND & AIMS: Endoscopic sleeve gastroplasty (ESG) is an incisionless, minimally invasive bariatric procedure that reduces the length and width of the gastric cavity to facilitate weight loss. We performed a prospective study to evaluate the effects of ESG on total body weight loss and obesity-related comorbidities. METHODS: We collected data from 91 consecutive patients (mean age, 43.86 ± 11.26 years; 68% female) undergoing ESG from August 2013 through March 2016...
December 23, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27986587/the-utility-of-weight-loss-medications-after-bariatric-surgery-for-weight-regain-or-inadequate-weight-loss-a-multi-center-study
#8
Fatima Cody Stanford, Nasreen Alfaris, Gricelda Gomez, Elizabeth T Ricks, Alpana P Shukla, Kathleen E Corey, Janey S Pratt, Alfons Pomp, Francesco Rubino, Louis J Aronne
BACKGROUND: Patients who undergo bariatric surgery often have inadequate weight loss or weight regain. OBJECTIVES: We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain. SETTING: Two academic medical centers. METHODS: We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000-2014...
October 27, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/27922026/percutaneous-gastrostomy-device-for-the-treatment-of-class-ii-and-class-iii-obesity-results-of-a-randomized-controlled-trial
#9
Christopher C Thompson, Barham K Abu Dayyeh, Robert Kushner, Shelby Sullivan, Alan B Schorr, Anastassia Amaro, Caroline M Apovian, Terrence Fullum, Amir Zarrinpar, Michael D Jensen, Adam C Stein, Steven Edmundowicz, Michel Kahaleh, Marvin Ryou, J Matthew Bohning, Gregory Ginsberg, Christopher Huang, Daniel D Tran, Joseph P Glaser, John A Martin, David L Jaffe, Francis A Farraye, Samuel B Ho, Nitin Kumar, Donna Harakal, Meredith Young, Catherine E Thomas, Alpana P Shukla, Michele B Ryan, Miki Haas, Heidi Goldsmith, Jennifer McCrea, Louis J Aronne
OBJECTIVES: The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling. METHODS: In this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0-55.0 kg/m(2) were randomly assigned in a 2:1 ratio to treatment with AspireAssist plus Lifestyle Counseling (n=137; mean BMI was 42...
March 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27700187/an-update-on-naltrexone-bupropion-extended-release-in-the-treatment-of-obesity
#10
Katherine H Saunders, Leon I Igel, Louis J Aronne
As the prevalence of obesity continues to increase, the need for effective long-term treatment strategies for the overweight and the obese is critical. Pharmacology fills a large treatment gap between behavioral therapy, which is insufficient for the majority of patients, and devices and surgery, which are available to only a subset of patients. Naltrexone HCl and bupropion HCl Extended-Release (naltrexone XR/bupropion XR) was approved by the Food and Drug Administration for chronic weight management in 2014...
October 4, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27623105/trimming-the-fat-endoscopic-suturing-for-tightening-of-prior-endoscopic-sleeve-gastroplasty
#11
Nikhil A Kumta, Rushabh Doshi, Louis J Aronne, Reem Z Sharaiha
No abstract text is available yet for this article.
January 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/27569120/low-adoption-of-weight-loss-medications-a-comparison-of-prescribing-patterns-of-antiobesity-pharmacotherapies-and-sglt2s
#12
Catherine E Thomas, Elizabeth A Mauer, Alpana P Shukla, Samrat Rathi, Louis J Aronne
OBJECTIVE: To characterize the adoption of antiobesity pharmacotherapies, as compared with that of the newest antidiabetes pharmacotherapy, subtype 2 sodium-glucose transport protein inhibitors (SGLT2s), among prescribers in the United States. METHODS: A retrospective analysis of 2012 to 2015 data extracted from the IMS Health National Prescription Audit™ and Xponent™ assessed adoption rates of antiobesity pharmacotherapies and SGLT2s. RESULTS: The number of dispensed antidiabetes prescriptions was 15 times the number of dispensed antiobesity prescriptions...
September 2016: Obesity
https://www.readbyqxmd.com/read/27519128/pharmacotherapy-for-obesity
#13
REVIEW
Katherine H Saunders, Alpana P Shukla, Leon I Igel, Rekha B Kumar, Louis J Aronne
Successful treatment of obesity requires a multidisciplinary approach including diet, exercise and behavioral modification. As lifestyle changes are not sufficient for some patients, pharmacologic therapies should be considered as adjuncts to lifestyle interventions. In this article, we review clinical indications, mechanisms of action, dosing/administration, side effects, drug interactions and contraindications for the six most widely prescribed obesity medications. We also summarize the efficacy data from phase 3 trials which led to drug approval...
September 2016: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/27252721/timing-of-false-ring-formation-in-pinus-halepensis-and-arbutus-unedo-in-southern-italy-outlook-from-an-analysis-of-xylogenesis-and-tree-ring-chronologies
#14
Veronica De Micco, Angela Balzano, Katarina Čufar, Giovanna Aronne, Jožica Gričar, Maks Merela, Giovanna Battipaglia
Mediterranean tree rings are characterized by intra-annual density fluctuations (IADFs) due to partly climate-driven cambial activity. IADFs are used as structural signals to gain information on relations between environmental conditions and eco-physiological processes during xylogenesis, with intra-annual resolution. To reach an unbiased synchronization of the IADF position within tree rings and seasonal fluctuations in environmental conditions, it is necessary to know the timing of cambial activity and wood formation, which are species- and site-specific processes...
2016: Frontiers in Plant Science
https://www.readbyqxmd.com/read/27181165/pharmacologic-approaches-to-weight-management-recent-gains-and-shortfalls-in-combating-obesity
#15
REVIEW
Katherine H Saunders, Rekha B Kumar, Leon I Igel, Louis J Aronne
Obesity is a growing epidemic in the USA with over one third of adults presently classified as obese. Obesity-related comorbidities include many leading causes of preventable death such as heart disease, stroke, type 2 diabetes, and certain types of cancer. Modest weight loss of 5-10 % of body weight is sufficient to produce clinically relevant improvements in cardiovascular disease risk factors among patients with overweight and obesity. Until recently, there were limited pharmacologic options approved by the Food and Drug Administration to treat obesity...
July 2016: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/27005405/effect-of-liraglutide-3-0%C3%A2-mg-in-individuals-with-obesity-and-moderate-or-severe-obstructive-sleep-apnea-the-scale-sleep-apnea-randomized-clinical-trial
#16
A Blackman, G D Foster, G Zammit, R Rosenberg, L Aronne, T Wadden, B Claudius, C B Jensen, E Mignot
BACKGROUND: Obesity is strongly associated with prevalence of obstructive sleep apnea (OSA), and weight loss has been shown to reduce disease severity. OBJECTIVE: To investigate whether liraglutide 3.0 mg reduces OSA severity compared with placebo using the primary end point of change in apnea-hypopnea index (AHI) after 32 weeks. Liraglutide's weight loss efficacy was also examined. SUBJECTS/METHODS: In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29...
August 2016: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/26888066/metformin-an-old-therapy-that-deserves-a-new-indication-for-the-treatment-of-obesity
#17
REVIEW
L I Igel, A Sinha, K H Saunders, C M Apovian, D Vojta, L J Aronne
Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment. Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety. Thus, metformin should be considered for a treatment indication in patients with these conditions.
April 2016: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/26512740/bupropion-sr-plus-naltrexone-sr-for-the-treatment-of-mild-to-moderate-obesity
#18
REVIEW
Khawla F Ali, Alpana P Shukla, Louis J Aronne
Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials.
2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26491591/original-solution-for-middle-ear-implant-and-anesthetic-surgical-management-in-a-child-with-severe-craniofacial-dysmorphism
#19
Giovanni Bianchin, Lorenzo Tribi, Aronne Reverzani, Patrizia Formigoni, Valeria Polizzi
We describe the novel solution adopted in positioning middle ear implant in a child with bilateral congenital aural atresia and craniofacial dysmorphism that have posed a significant challenge for the safe and correct management of deafness. A five-year-old child, affected by a rare congenital disease (Van Maldergem Syndrome), suffered from conductive hearing loss. Conventional skin-drive bone-conduction device, attached with a steel spring headband, has been applied but auditory restoration was not optimal...
2015: Case Reports in Otolaryngology
https://www.readbyqxmd.com/read/26481564/the-2013-american-heart-association-american-college-of-cardiology-the-obesity-society-guideline-for-the-management-of-overweight-and-obesity-in-adults-what-is-new-about-diet-drugs-and-surgery-for-obesity
#20
keyword
keyword
56225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"